Page last updated: 2024-11-08

vasobral

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Vasobral: cerebroprotective agent containing dihydroergocryptine and caffeine [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID175613
MeSH IDM0156422

Synonyms (5)

Synonym
vasobral
ergotaman-3',6',18-trione, 9,10-dihydro-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-, (5'alpha,10alpha)-, monomethanesulfonate (salt), mixt. with 3,7-dihydro-1,3,7-trimethyl-1h-purine-2,6-dione
(5'alpha,10alpha)-9,10-dihydro-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)ergotaman-3',6',18-trione mixt. with 3,7-dihydro-1,3,7-trimethyl-1h-purine-2,6-dione
94423-99-1
(6ar,9r,10ar)-n-[(1s,2s,4r,7s)-2-hydroxy-7-(2-methylpropyl)-5,8-dioxo-4-propan-2-yl-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline-9-carboxamide;methanesulfonic acid;1,3,7-trimethylpurine-2,6

Research Excerpts

Actions

ExcerptReferenceRelevance
"Vasobral did not cause significant fluctuations of arterial pressure and was safe for patients with chronic vascular encephalopathy and arterial hypertension."( [Efficacy of the combination drug vasobral in chronic vascular encephalopathy].
Barantsevich, ER; Belskaya, GN; Kopishinskaya, SV; Levin, OS; Lukashevich, IG; Ostroumova, OD; Psokhina, OV; Radiuk, MA; Vasenina, EE, 2014
)
1.4

Dosage Studied

ExcerptRelevanceReference
" The trial included 5475 patients treated with vasobral in dosage 2 ml (1 ml contains 1 mg of alpha-dihydroergocryptine and 10 mg of caffeine) twice a day during 2 months."( [Preventive treatment of migraine with vasobral: a multicenter trial].
Azimova, IuE; Tabeeva, GR, 2010
)
0.89
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (11.11)18.7374
1990's1 (11.11)18.2507
2000's2 (22.22)29.6817
2010's5 (55.56)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 41.96

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index41.96 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index4.73 (4.65)
Search Engine Demand Index56.64 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (41.96)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (20.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational1 (10.00%)0.25%
Other7 (70.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]